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Abstract
Malignant melanoma is a refractory malignancy with a dismal prognosis. It generally arises from the skin in most
cases, and cases of primary pulmonary malignant melanoma are rare and often behave aggressively. We have
treated two cases of localized primary pulmonary malignant melanoma using surgical resection. Pulmonary
malignant melanomas often metastasize to the brain and liver; one of our cases exhibited metastasis to the cecum
at about 8 months after surgery. Because cutaneous melanomas often carry activating mutations in the BRAF gene
(V600E), we performed a BRAF mutational analysis using direct sequencing for both of these tumors arising from
the lung. However, no BRAF mutations were detected. We detected a p53 mutation, which was thought to be a
potential somatic mutation, in one of the two cases using a sequencing panel targeting 20 lung cancer-related
genes. Although we also checked the expression of programmed death ligand 1 (PD-L1) on the surface of the
tumor cells by immunohistochemical testing, neither of our two cases expressed PD-L1. Further molecular analyses
may uncover the characteristics of primary pulmonary malignant melanomas.
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Background
Malignant melanoma is an often fatal cutaneous neoplasm.
As a primary tumor, malignant melanoma of the lung is
rare, accounting for only 0.01 % of all primary lung tumors
[1]. To diagnose malignant melanoma as a primary tumor
arising from the lung, the absence of primary melanoma
lesions at cutaneous or nonpulmonary extracutaneous sites
must be demonstrated [2].
Approximately 40 to 60 % of cutaneous melanomas
carry mutations in the BRAF gene (V600E), which leads
to the constitutive activation of downstream signaling
through the MAPK pathway [3, 4]. At present, whether
pulmonary malignant melanomas carry BRAF mutations
has not been reported. Additionally, immunotherapy to
inhibit programmed death 1 (PD-1)/programmed death
ligand 1 (PD-L1) pathway that has a role for immune escape
is developed for malignant melanoma [5, 6]. It is reported
that the efficacy of anti-PD-1 antibody was related to the
expression of PD-L1 in tumor cells [6]. Here, we describe
two cases of possible primary pulmonary malignant melan-
oma with wild-type BRAF and no expression of PD-L1.
Case presentation
Case 1
A 66-year-old man with hemoptysis was referred to our
hospital because of a pulmonary malignant tumor. A
bronchoscopy revealed a tumor arising from the right
middle lobe bronchus (Fig. 1a), and a histological diag-
nosis based on a bronchial biopsy revealed a malignant
melanoma. A positron emission tomography-computed
tomography (PET-CT) scan revealed no other lesions
that could have represented a primary site (Fig. 1b). A
right middle lobectomy with mediastinal and hilar lymph-
adenectomy was performed. Some tumor cells had melanin
in the cytoplasm (Fig. 1c). Immunohistochemical analysis
showed positive cytoplasmic staining of the tumor cells for
HMB-45, Tyrosinase, and MART1, although the expres-
sion of TTF-1 in tumor cells was negative. The postopera-
tive course was uneventful. Combination chemotherapy of
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dacarbazine, nimustine, and vincristine was performed. At
the time of the 22 months after surgery, he was alive with-
out disease recurrence.
Case 2
A 46-year-old woman was found to have an abnormal
shadow on a chest X-ray during an annual check-up. A
CT and PET-CT scan showed a tumor in the left lower
lobe of the lung (Fig. 2a, b). Pathological examination of
a specimen obtained during a transbronchial lung biopsy
revealed that the tumor was a malignant melanoma
(Fig. 2c). Because further examinations did not reveal any
other tumors that could have been the primary lesion, we
diagnosed the lung tumor as a primary pulmonary malig-
nant melanoma. A left lower lobectomy with mediastinal
and hilar lymph node dissection was performed. Immuno-
histochemical staining was negative for S-100 protein,
chromogranin, synaptophysin, keratin, and TTF-1 but
positive for HMB-45 and vimentin. The postoperative
course was uneventful. She refused to receive adjuvant
chemotherapy. Eight months after the pulmonary resec-
tion, a PET-CT scan showed the uptake of fluorodeoxyglu-
cose in the cecum (Fig. 2e). An ileocecal resection was
performed, and the pathological examination indicated
that the tumor was considered to be the recurrence of a
melanoma.
Molecular profiling
We determined the BRAF mutational status (exons 11 and
15) using direct sequencing in the two tumors. The detailed
methods have been described previously [7]. However, we
did not detect any BRAF mutations. Next, we performed a
target sequencing analysis using the Human Lung Cancer
Panel (Qiagen, Hilden, Germany), which targets 20 lung
cancer-related genes including most of the exons in BRAF,
using the same samples. Although various variants were
detected using this analysis, only the p53 mutation (P72R)
in case 1 was considered to be a potential somatic mutation
after restricting the variants using GeneRead Software
(Qiagen, Venlo, Netherlands) as shown in Table 1. P72R
mutation has been already reported in bladder and gastric
cancers, but there are no reports in lung cancer or malig-
nant melanoma ([8], accessed on August 14, 2015).
Furthermore, we also checked the expression of PD-L1
on the surface of the tumor cells by immunohistochemical
testing in formalin-fixed, paraffin-embedded tumor speci-
mens with the use of a rabbit monoclonal antihuman PD-
L1 antibody. In the previous reports, PD-L1 positivity was
defined as at least 5 % of tumor cells showing cell-surface
Fig. 1 Diagnostic images and pathological findings for case 1. a A bronchoscopy revealed a tumor arising from the right middle lobe bronchus.
b PET-CT scan revealed no other lesions that could have represented a primary site. c Hematoxylin-eosin staining of the resected tumor, ×40
(scale bar, 100 μm). d Immunohistochemistry showed negative for PD-L1 staining, ×40 (scale bar, 100 μm)
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PD-L1 staining of any intensity in a section containing at
least 100 tumor cells that could be evaluated [9, 10].
According to the definition of PD-L1 positivity by them,
neither of our two cases was considered to express PD-L1
(Figs. 1d and 2d).
Discussion
The total number of operations in general thoracic surgery
is increasing year by year in Japan [11]. However, there are
a few reports about primary pulmonary melanoma [2].
There are four clinical criteria that should be satisfied for
the diagnosis of primary melanoma of the lung: (1) no pre-
viously removed skin tumor, unless the pathology examin-
ation did not show malignancy and the slides are still
available for reevaluation; (2) no excised ocular tumor; (3) a
solitary tumor in the surgical specimen from the lung; and
(4) no demonstrable melanoma in other organs at the time
of surgery [1, 12]. Both of our cases fulfill the abovemen-
tioned diagnostic criteria.
Regarding treatment, surgery is necessary for a cure for
localized pulmonary malignant melanoma because the
effect of chemotherapy on malignant melanoma is limited
[13]. Even among patients who undergo surgery, the prog-
nosis of patients with malignant melanoma of the lung is
generally poor because the lesion often metastasizes soon
after surgery. Regarding metastatic spread, primary pul-
monary melanomas often metastasize to the brain and the
liver [2, 14–16], similar to other types of primary lung can-
cer. Intriguingly, one of our cases exhibited metastasis to
the cecum. To the best of our knowledge, this is the first
report describing a malignant melanoma of the lung metas-
tasizing to the cecum.
BRAF-activating mutation is a characteristic of malignant
melanoma, and molecular-targeted therapy for BRAF has
been developed [17]. However, our two cases did not
exhibit activating mutations in BRAF. Considering the fact
that the presence of BRAF-activating mutations has not
been reported in pulmonary malignant melanoma, their
features may differ from those of primary skin melanoma.
A target sequencing analysis did not detect any possible
somatic driver mutations commonly observed in lung
cancer [18], such as EGFR, HER2, KRAS, ALK, MET, or
PIK3CA, suggesting that primary pulmonary malignant
melanomas may have different oncogenic pathways
from primary lung cancer from the viewpoint of driver
oncogenes.
In these days, there are many reports about the efficacy
of anti-PD-1 antibody for cutaneous melanoma patients
Fig. 2 Diagnostic images and pathological findings for case 2. a A CT scan shows a large tumor in the left lower lobe of the lung. b Preoperative PET-CT
scan revealed no other lesions that could have represented a primary site. c Hematoxylin-eosin staining of the resected tumor, ×40 (scale bar, 100 μm). d
Immunohistochemistry showed negative for PD-L1 staining, ×40 (scale bar, 100 μm). e Eight months after the pulmonary resection, PET-CT scan showed
the uptake of fluorodeoxyglucose in the cecum
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and a potential association between the occurrence of a
response and expression of PD-L1 in patients receiving
nivolumab [10]. On the other hand, Robert et al. reported
that regardless of PD-L1 status, nivolumab-treated
patients had improved overall survival, as compared
with dacarbazine-treated patients [19]. Although our
findings did not show the positivity of PD-L1 in the
two cases, there is still the possibility of the efficacy of
immunotherapy for primary pulmonary melanoma, as
the role of PD-1/PD-L1 pathway in primary pulmon-
ary melanoma is yet to be investigated.
Conclusions
In conclusion, we encountered two cases of malignant mel-
anoma of the lung that did not carry activating mutations
in the BRAF gene. Further molecular analyses may uncover
the characteristics of primary malignant melanoma.
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